MedTrace Logo

Incidence of Platelet Refractoriness in Adult Acute Leukemia Patients Receiving Prestorage Filtered Blood and Comparing With Historical Control

NCT06325553 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 252

Last updated 2024-03-22

No results posted yet for this study

Summary

This research project is evaluate the incidence of platelet refractoriness in newly diagnosed acute leukemia patients receiving PFB during induction and first consolidation phase chemotherapy compared to 2 historical control groups which are patients receiving non-leukocyte depleted blood product group and leukocyte depleted blood product group and demonstrate cost-effectiveness of using blood products with filtered process to prevent clinical platelet refractoriness compare with using HLA-matched blood products after platelet refractoriness occurs

Conditions

  • Platelet Refractoriness in Adult Acute Leukemia

Sponsors & Collaborators

  • Siriraj Hospital

    lead OTHER

Principal Investigators

  • weerapat Owattanapanich, MD · Siriraj Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-30
Primary Completion
2025-03-30
Completion
2026-03-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06325553 on ClinicalTrials.gov